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Abstract
Background:  Walking along disease-associated protein sequences in the search for specific
segments able to induce cellular immune response may direct clinical research towards effective
peptide-based vaccines. To this aim, we are studying the targets of the immune response in
autoimmune diseases by applying the principle of non-self-discrimination as a driving concept in the
identification of the autoimmunogenic peptide sequences.
Methods: Computer-assisted proteomic analysis of the autoantigen protein sequence and dot-
blot/NMR immunoassays are applied to the prediction and subsequent validation of the epitopic
sequences.
Results: Using the experimental model Pemphigus vulgaris/desmoglein 3, we have identified the
antigenic linear determinant recognized by MAb 5H10, a monoclonal antibody raised against the
extracellular domain of human desmoglein-3. The computer-assisted search for the Dsg3 epitope
was conducted by analyzing the similarity level to the mouse proteome of the human desmoglein
protein sequence. Dot-blot immunoassay analyses mapped the epitope within the sequence
Dsg349–60  REWVKFAKPCRE, which shows low similarity to the mouse proteome. NMR
spectroscopy analyses confirmed the specificity of MAb 5H10 for the predicted epitope.
Conclusions: This report promotes the concept that low level of sequence similarity to the host's
proteome may modulate peptide epitopicity.
Introduction
In the last decades, several computer-driven algorithms
have been devised to take advantage of the linear repre-
sentation of protein sequence information to search for
epitopic motifs [1-5]. These algorithms search the amino
acid sequence of a given protein for characteristics
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believed to be common to antigenic peptides, locating
regions that are likely to induce cellular immune
response. Given the rapid expansion of proteomic
sequence data, the application of these algorithms to dis-
ease-associated proteins may direct research to specific
segments of disease-associated proteins and thus poten-
tially reduce the time and effort needed to develop effec-
tive vaccines [6,7].
We are using in silico technology platforms to identify
epitopic peptide sequence(s) from disease-associated-
antigens by following the hypothesis that peptide
epitopicity might be regulated by the peptide similarity
level to the host's proteome, in addition to other factors
such as MHC binding potential [8-10]. As a scientific
rationale, we follow the criterion that immune system
might be allowed/forced to respond only to rarely
encountered/never seen antigenic sequences. Accordingly,
we explain the non-immunogenicity of tumor-associated-
antigens as due to high level of similarity of oncoprotein
sequences to self-proteome [8,9,12].
In this context we have tested here the possibility that
endogenous, normal, housekeeping self-proteins har-
bouring sequences with little or no similarity to the collec-
tive host proteome might be epitopic targets in
autoimmune responses. Self-reactivity and autoimmunity
are processes related to the breakage of self-tolerance that
can be distinguished by their different clinical outcome.
The transition from self-reactivity to the autoimmune
pathology appears to be mediated by a complex network
of overlapping phenomena that comprehend epitope
spreading, uncovering of cryptic epitopes, natural autoan-
tibodies production, cross-reactivity, microchimerism,
altered B lymphocyte function, inflammation, etc. [13]. In
our labs, we are studying the autoantibody profile in Pem-
phigus vulgaris (PV). PV is an autoimmune bullous skin
disease characterized by autoantibodies to a desmosomal
adhesion molecule, the cadherin desmoglein-3 (Dsg3)
[14]. Dsg3 represents an optimal autoantigen for studying
the relationship between similarity level and immune
responses. Indeed the PVA Dsg3 is a highly conserved pro-
tein, and the human and mouse forms present 71.6% of
identity. Therefore, this protein allows to analyze the
sequence specificity of the reaction PVA-autoantibody by
using murine monoclonal antibodies. Moreover, our
interest to study the autoantibody response in this
autoimmune disease also stems from the following con-
siderations: i) so far, notwithstanding the Dsg3 linear
structure, attention has been focused mainly on confor-
mational Dsg3 epitopes [15-18] and there is a lack of data
on the occurrence and fine molecular characterization of
linear Dsg3 epitopes; ii) although the precise pathological
implications of anti-Dsg autoantibodies are not fully elu-
cidated [19-23], it seems likely that a spectrum of autoan-
tibodies, differing in number and type, might contribute
to the autoimmune pathology in PV [24]. Given these
premises, the development of new experimental
approaches that might lead to the exact definition of lin-
ear PVA epitopes is desirable. As a first attempt to a com-
puter-driven individuation of defined linear epitopic
sequences of Dsg3, we describe here the identification of
the linear epitope of the MAb 5H10 raised in BALB/c mice
against the extracellular domain (EC1/EC2, aa1-212) of
human Dsg3.
Materials and methods
Computer-assisted analyses
The amino acid sequence corresponding to accession
number P32926, SWISS-PROT, was used in the similarity
analysis of the extracellular domain of human Dsg3 (EC1
to part of EC2, amino acid 1–212) to the mouse pro-
teome. The Dsg3 sequence under analysis was dissected
into pentamer motifs, that were probed for sequence sim-
ilarity to mouse proteome by using PIR non-redundant
reference protein database and peptide match program
http://pir.georgetown.edu/pirwww[25]. The search was
conducted against mouse complete genome for a total of
78435 sequences, and includes hypothetical/unidentified
proteins sequences.
Antibodies
Anti-Dsg3 MAb 5H10 and 5G11, raised in BALB/c mice,
were a generous gift of Dr. Margaret Wheelock, University
of Toledo, Ohio. Both MAbs recognize a linear determi-
nant and have been described in detail [26]. Briefly, MAb
5H10 has been shown to recognize the amino terminal
part of the extracellular domain of Dsg3 (EC1 to part of
EC2, amino acid 1–212). MAb 5G11 reacts with the car-
boxyl terminus of the EC domain of Dsg3 (part of EC4 to
EC5, amino acid 446–613). Horseradish peroxidase
(HRP)-conjugated goat anti-mouse IgG-specific Abs was
from Sigma, Chemical Co., St.Louis, Mo.
Synthetic peptides
Peptides were synthesized using standard Fmoc (N-(9-flu-
orenyl)methoxycarbonyl) solid phase peptide synthesis.
Peptide purity (>90%) was controlled by analytical HPLC,
and the molecular mass of purified peptides confirmed by
fast atomic bombardment mass spectrometry. The EC1/
EC2 Dsg336–45EEMTMQQAKR, Dsg349–
60REWVKFAKPCRE, and Dsg3173–187  NSLVMILNAT-
DADEP peptides were obtained from PeptidoGenic
Research & Co., Livermore, CA., and used in dot-blot
immunoassay experiments. Human recombinant Dsg3
protein was used as further control [27]. The 15N-labelled
synthetic peptide Dsg349–60REWVKFAKPCRE (where 15N-
labelled amino acid residues are underlined) was from
Primm srl, Milan, Italy. Peptides were dissolved in 0.9%
NaCl, aliquoted and stored at -20°C.Journal of Translational Medicine 2004, 2:43 http://www.translational-medicine.com/content/2/1/43
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Dot immunoassay
Nitrocellulose membrane (0.2 µm pore size, BioRad Lab-
oratories, Hercules, CA) was pretreated for 10 min with
1.0% glutaraldehyde. Synthetic peptides were spotted on
the activated membranes, left to dry at RT and exposed to
UV rays for 10 min. Membranes were incubated for 1 h in
phosphate-buffered saline/0.05% (v/v) Tween 20 (PBST)
containing 4% bovine serum albumin (BSA), and then
with the primary MAb (1:800) for further 2 h. Membranes
were washed for 10 min with PBST (x3) and incubated in
PBST/4% BSA with HRP-conjugated affinity-purified goat
anti-mouse IgG (1:1000) for 1 h. Membranes were
washed in PBST for 5 min (x3), in PBS for 5 min (x3) and
immunoblots were developed using the enhanced chemi-
luminescence detection assay (Renaissance, NEN™ Life
Science Products, Boston, MA.) following supplier's
instructions.
NMR spectroscopy
NMR spectra of the reaction between the synthetic 15N-
labelled peptide Dsg349–60REWVKFAKPCRE (where 15N-
labelled amino acid residues are underlined) and MAb
5H10 (raised against EC1/EC2 from Dsg3) or 5G11
(raised against EC4/EC5 from Dsg3) were recorded at
298°K on a Bruker Avance DRX500WB spectrometer. The
spectra were acquired by heteronuclear single quantum
correlation (HSQC) experiments that correlate the chem-
ical shift of proton with the chemical shift of the directly
bonded nitrogen. Specifically, the two-dimensional 1H-
15N inverse detected correlation spectra were acquired by
the gradient pulse sensitivity improved Bruker automa-
tion program INVIETGPSI [28]. The 1H acquisition
dimension was collected with a spectral width of 5 ppm,
centered at 7.6 ppm, using 4096 datapoints for each of the
total 32 scans/expt. Spectral width in the indirect detected
15N dimension was 200 ppm, centered at 90 ppm,
obtained with a total of 1024 points. The spectra were
processed by XwinNMR program, version 2.6, running on
an INDY R5000 Silicon Graphics Workstation. Chemical
shift values were referenced to sodium tetrasilyl propion-
ate (TSP) (1H; 0.000 ppm) and external neat nitrometh-
ane (15N; 380.23 ppm) standards. To avoid interferences
Molecular mimicry between the EC1/EC2 of human Dsg3 and mouse proteome Figure 1
Molecular mimicry between the EC1/EC2 of human Dsg3 and mouse proteome. The EC1/EC2 Dsg3 sequence 
(aa1-212) was scanned for matches to mouse protein sequences by using pentamers offset by one residue. The arrow indicates 
the longest stretch having the lowest number of matches.Journal of Translational Medicine 2004, 2:43 http://www.translational-medicine.com/content/2/1/43
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of TSP standard with peptide samples, the instrument
scale was preliminarily calibrated in parallel experiments
with samples containing the peptide to be analysed plus
0.2 mg TSP. We used chemical shift statistics from the full
BioMagResBank database, where the calculated statistics
are derived from a total of 559392 chemical shifts (web-
site: http://www.bmrb.wisc.edu/ref_info/statful.htm).
Sequence-specific correction factor tabulations were
applied to backbone 1H and 15N resonances [29]. Two-
dimensional correlated spectroscopy spectra of MAb-pep-
tide complex were obtained using a 1:2 stoicheiometric
molar ratio (peptide:MAb, 0.1:20, mg/mg). That is, NMR
samples contained either 0.1 mg free REWVKFAKPCRE
peptide, or 20 mg MAb 5H10 complexed with 0.1 mg
REWVKFAKPCRE peptide, or 20 mg MAb 5G11 com-
plexed with 0.1 mg REWVKFAKPCRE peptide, in 0.5 ml
aqueous solution H2O/D2O (9:1, v/v).
Results
Selection of Dsg3 peptide sequences with low similarity to 
the mouse proteome
The EC1/EC2 domain (aa1-212) of human Dsg3 was dis-
sected into 5-mer sequences and analyzed for similarity to
mouse proteins. The pentamers used for epitope scanning
were offset by one residue, i.e. overlapped by 4 residues:
MMGLF, MGLFP, GLFPR, LFPRT, etc. The 5-mer
sequences were probed in computer-assisted similarity
analyses against the complete mouse genome sequences.
Fig. 1 reports the profile we obtained by representing the
number of matches to mouse proteome over the sequen-
tial pentamer peptides. It can be seen that the EC1/EC2
Dsg3 protein sequence presents stretches scarcely repre-
sented in the mouse proteome. Among the low-similarity
EC1/EC2 Dsg3 peptide fragments, the Dsg349–
60REWVKFAKPCRE sequence was the longest (12 amino
acid residues long) with the lowest number of matches to
the murine proteome (number of matches to murine pro-
teome = 9). The Dsg349–60REWVKFAKPCRE sequence and
a second low-similarity fragment, Dsg336–
45EEMTMQQAKR (number of matches to murine pro-
teome = 12), were selected to test our hypothesis.
Dot-blot immunoassay
The two low similarity peptides selected as described
above were synthetised in order to be assayed in immun-
odot-blot analyses to identify the linear determinant of
the MAb 5H10. In addition, the synthetic Dsg3173–
187NSLVMILNATDADEP peptide (matches to murine pro-
teome = 109) was available and served as a high similarity
peptide control. The three synthetic peptides are described
in Fig. 2. The MAb 5G11 with specificity to the terminal
EC portion of Dsg3, amino acid 446–613 [26] was used as
a primary antibody control. The immunodot-blot experi-
mental result is illustrated in Fig. 3. It can be seen that
MAb 5H10 recognized peptide n. 2, i.e. the Dsg349–
60REWVKFAKPCRE sequence having a lowest level of sim-
ilarity to the mouse proteome (see Fig. 1). No reaction
was monitored using MAb 5G11.
NMR spectroscopic immunoanalysis
As a further step, we carried out a parallel experimental
confirmation because of the doubts of false negative/pos-
itive data intrinsic to immunoassay. To this aim, the bind-
ing of the predicted epitopic Dsg349–60REWVKFAKPCRE
peptide and the mouse anti-Dsg3 5H10 MAb was further
verified by NMR spectroscopy. NMR spectroscopy can be
Similarity scanning on the human Dsg3 peptide sequences  selected for immunoassay analysis with murine anti-EC1/EC2  Mab 5H10 Figure 2
Similarity scanning on the human Dsg3 peptide 
sequences selected for immunoassay analysis with 
murine anti-EC1/EC2 Mab 5H10. Matching analysis to 
the murine proteome was performed using as probes pen-
tamers offset by one residue as described under Methods. 
Peptide: 1) Dsg336–45EEMTMQQAKR; 2) Dsg349–
60REWVKFAKPCRE; 3) Dsg3173–187NSLVMILNATDADEP.Journal of Translational Medicine 2004, 2:43 http://www.translational-medicine.com/content/2/1/43
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Identification of the epitopic sequence recognized by mouse anti-Dsg31–212 MAb 5H10 Figure 3
Identification of the epitopic sequence recognized by mouse anti-Dsg31–212 MAb 5H10. Dot-blot immunoassay was 
performed on nitrocellulose membrane spotted with human Dsg3 (10µg), or Dsg3 peptide (2.5µg) corresponding to the 
sequence: 1) Dsg336–45EEMTMQQAKR; 2) Dsg349–60REWVKFAKPCRE; 3) Dsg3173–187NSLVMILNATDADEP.
Table 1: Sequence-specific assignments in the 15N-labelled Dsg349–60REWVKFAKPCRE peptide, and chemical shift changes on MAb 
5H10 or 5G11 binding.
15N-Amino 
acid
Chemical Shift Values:
Theoretical: 
Free peptide
Experimental: 
Free peptide +MAb 5H10 +control MAb 5G11
1HN1 5 N 1HN1 5 N 1HN1 5 N 1HN1 5 N
Arg-1 6.78 77.6 6.95 81.0 n.d. n.d. 7.05 80.5
Val-4 8.65 120.8 8.19 122.8 n.d. n.d. 8.18 122.5
Phe-6 8.42 121.7 7.99 119.2 n.d. n.d. 8.00 118.9
Ala-7 8.29 122.3 8.40 120.0 n.d. n.d. 8.44 120.2
Arg-11 6.78 77.6 7.25 81.5 n.d. n.d. 7.26 81.0
8.14 119.6 8.16 118.1 n.d. n.d. 8.15 117.8
The 15N-amino acid position in the peptide is reported. Theoretical chemical shift values were derived from http://www.bmrb.wisc.edu/ref_info/
statful.htm and corrected [29]. Experimental chemical shift values were derived from resonance spectra reported in Fig. 4. The average value of 
chemical shifts relative to the H and N atoms of α amino residue, and the H and N atoms of η amino residues are reported for Arg-11 (data from: 
http://www.bmrb.wisc.edu/ref_info/statful.htm). The chemical shifts relative to the H and N atoms of α amino residue in Arg-1 are undetectable 
because of terminal position of the amino acid in the peptide. n.d., not detected.Journal of Translational Medicine 2004, 2:43 http://www.translational-medicine.com/content/2/1/43
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used in 1) defining structure and conformation; 2) defin-
ing structure-activity relationships; 3) monitoring
chemical reactions. Informations are mainly derived by
measuring NMR chemical shifts. The chemical shift of a
nucleus is the difference between the resonance frequency
of the nucleus and a standard. This quantity is reported in
parts per million (ppm). The NMR standards are mole-
cules as tetrasilyl propionate, the signal of which is set at
0 ppm by having shielded protons. The NMR chemical
shift allows for distinguishing magnetically inequivalent
nuclei in a molecule, i.e. chemical shifts are a measure of
the motional freedom.
We utilized NMR spectroscopy in order to determine
whether the predicted peptide specifically binds to the
MAb 5H10. To this aim, a 15N-labelled REWVKFAKPCRE
peptide(where  15N-labelled amino acid residues are
underlined) was synthesized. Theoretical chemical shift
values of the 15N-labelled residues in the Dsg349–60
REWVKFAKPCRE peptide were calculated as described
under Methods, and then were compared to the experi-
mental values. Table 1 lists the theoretical and experimen-
tal chemical shift values of 15N-labelled residues in the
Dsg349–60 REWVKFAKPCRE peptide, and their values fol-
lowing addition of MAb 5H10 or MAb 5G11.
The resonance spectra of the reaction between MAb 5H10
and the 15N-labelled Dsg349–60 REWVKFAKPCRE peptide
are illustrated in Fig. 4. Each "spot" in the figure is an
NMR signal representing the 1H-15N one-bond coupling
1H-15N NMR HSQC spectra and relative 1-D contour plots of the Dsg349–60REWVKFAKPCRE peptide 15N-labelled at residues  7, 10, 12 and 14 (A), plus MAb 5H10 (B), or 511G (C) Figure 4
1H-15N NMR HSQC spectra and relative 1-D contour plots of the Dsg349–60REWVKFAKPCRE peptide 15N-
labelled at residues 7, 10, 12 and 14 (A), plus MAb 5H10 (B), or 511G (C). Upper panels report portions of the 
HSQC spectra showing resonances from residues 1, 4, 6, 7, and 11. Lower panels report expanded region of the HSQC spec-
tra showing resonances from the same residues 4, 6, 7, and 11.Journal of Translational Medicine 2004, 2:43 http://www.translational-medicine.com/content/2/1/43
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of the labelled amino acid residues in the peptide. In Fig.
4A, the reported spots correspond to the Arg, Val, Phe and
Ala selective 1H-15N correlation signals of the free peptide
in aqueous solution. As already illustrated in Table 1, the
expected signals are present and in basic agreement with
theoretical data (see BioMagResBank database, http://
www.bmrb.wisc.edu) following sequence-dependent cor-
rection of random coil NMR chemical shifts. [29]. The
upper panel of Fig. 4A displays the two Arg cross-peak sig-
nal, i. e. the chemical shifts relative to the H and N atoms
of amino   residues. The lower panel in fig. 4A reports the
cross-signal of 15N-Arg-11 whereas the 15N-Arg-1 was
undetectable because of the terminal position in the pep-
tide. Fig. 4B documents that the addition of MAb 5H10
caused the loss of 15N-labelled residue spectral resonance
signals thus indicating a complete loss of Dsg349–
60REWVKFAKPCRE peptide mobility. In contrast to the
total signal deletion provoked by MAb 5H10, the chemi-
cal shift values of the Dsg349–60 REWVKFAKPCRE peptide
remained unaltered following the addition of the anti-
Dsg3 MAb 5G11 (Fig. 4C, upper and lower panels).
Discussion
The present data appear of interest since, as a preliminary
consideration, it has to be noted that historically the
search for biologically relevant epitopic sequences has
demanded and still demands complicated procedures and
expensive technologies [30]. Here, the low-similarity prin-
ciple we used has allowed the utilization of proteomic
computational program for the exact epitope definition of
a MAb directed towards a 212 amino acid sequence by
using only 3 synthetic peptide reagents. Minimally, the
screening of a library of at least 14 non-overlapping pep-
tides, each 15 residues in length, would be necessary in
the unassisted case. Moreover, the individuation of the
Dsg349–60REWVKFAKPCRE motif as the antigenic epitope
of the Dsg3 EC1/EC2 domain, aa1-212, might contribute
to the understanding of the autoimmune mechanisms in
PV. This immunogenic sequence is hosted in the NH2 ter-
minal region of Dsg3, which has adhesive function in
cadherins [31] and contains the major epitopes recog-
nized by sera from PV patients [32]. Further, chimeric tox-
ins containing the Dsg3 EC1/EC2 domain, aa1-212, have
been demonstrated to downregulate anti-Dsg3 IgG-pro-
ducing B cells in mice immunized with Dsg3 aa1-212
[26].
In a wider context, the epitope mapping approach here
described might be helpful in defining peptide antigenic-
ity in a wide spectrum of human diseases including cancer
pathologies as well as a range of diverse autoimmune dis-
orders such as insulin-dependent diabetes mellitus, mul-
tiple sclerosis, rheumatoid arthritis, and Pemphigus
vulgaris. The fine profiling of the disease-associated
epitopic peptide repertoire is of particular importance in
the definition of qualities as antigenicity and immunodo-
minance, and is an essential preliminary step towards
effective immunotherapeutical treatments in cancer and
autoimmune pathologies. In synthesis, given the caveat
that only linear sequences can be defined by the analysis
of amino acid motif sharing by two or more proteins, the
epitope prediction model we report could form the basis
of a rapid, inexpensive and computationally driven sys-
tem for the individuation of antigenic sequences that are
the targets of autoimmune responses. Consequently, this
proteomic strategy may serve as a general method suitable
to define/distinguish/screen disease-(ir)relevant epitopes
within potential autoantigens with clinical application to
wide ranging human diseases where the precise targets of
self-directed attack are unknown [33].
Abbreviations
Dsg3, desmoglein 3; EC, extracellular; PVA, Pemphigus vul-
garis  autoantigen; PIR, Protein Information Resource;
HSQC, heteronuclear single quantum correlation.
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